AAMESO AS
Operating
Tilby konsulenttjenester til oppstart og etablerte selskaper innenfor
bio-medisinsk forskning og utvikling av teknologi og biologiske
legemiddler. Tilby kompetanse innenfor forretningsstrategi,
forretningsutvikling, produktutvikling og implementering av GMP
produksjon.
Konsulenttjenester rettet mot oppstarts-bedrifter innenfor
legemiddelindustrien i Norge, Europa og USA. Selskapet fokuserer
spesielt på biologisk-baserte legemidler til behandling kreft,
infeksjons- og autoimmune sykdommer.
Organization
- CEO
- ØÅ
Øystein Åmellem1958
- Chairman of the board
- ØÅ
Øystein Åmellem1958
- Years since formation
- 4 years
- since Nov 10, 2022
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 1,000
- 1 share class
- Total number of shareholders
- 1
- person
Financials
- Total operating income 2025
- 495,000
- NOK
- Annual total result 2025
- 29,734
- NOK
- Total equity 2025
- 1,631,729
- NOK
Last update: Jun 30, 2026
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
ØÅ 1958 | Managing Director/CEO | 100 % directly |
Board
| Name | Role | Shares |
|---|---|---|
ØÅ 1958 | Chairman | 100 % directly |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
ØÅ 1958 | Managing Director/CEO, Chairman | 100 % directly |
Last update: Apr 13, 2023
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
ØÅ 1958 | Ordinary shares | 1,000 | 100 % |
Shares owned by the AAMESO AS
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 1,823 | 1.26 % |
Last update: Jun 2, 2025
Financials
in NOK
Summary
| Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
Total operating income | 495,000 | 1,540,000 | 1,045,000 | 275,000 |
Annual Total Result | 29,734 | 783,365 | 785,917 | 208,283 |
Total assets | 2,375,325 | 2,313,448 | 1,512,500 | 289,888 |
Total liabilities | 743,596 | 711,452 | 693,870 | 57,175 |
Total equity | 1,631,729 | 1,601,996 | 818,630 | 232,713 |
P&L
| Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
Total operating income | 495,000 | 1,540,000 | 1,045,000 | 275,000 |
Total operating costs | 475,027 | 535,686 | 36,504 | 3,972 |
Operating result | 19,973 | 1,004,314 | 1,008,496 | 271,028 |
Financial income/costs | 14,155 | 0 | 0 | -5,570 |
Profit before tax | 34,128 | 1,004,314 | 1,008,496 | 265,458 |
Total tax & extraordinary income/cost | 4,394 | 220,949 | 222,579 | 57,175 |
Annual Total Result | 29,734 | 783,365 | 785,917 | 208,283 |
Balance overview
| Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
Total fixed assets | 644,349 | 137,500 | 302,500 | 0 |
Total current assets | 1,730,976 | 2,175,948 | 1,210,000 | 289,888 |
Total assets | 2,375,325 | 2,313,448 | 1,512,500 | 289,888 |
Short term debt | 743,596 | 711,452 | 693,870 | 57,175 |
Long term debt | 0 | 0 | 0 | 0 |
Total liabilities | 743,596 | 711,452 | 693,870 | 57,175 |
Contributed capital | 30,000 | 30,000 | 30,000 | 24,430 |
Retained earnings | 1,601,729 | 1,571,996 | 788,630 | 208,283 |
Total equity | 1,631,729 | 1,601,996 | 818,630 | 232,713 |
Total equity and liabilities | 2,375,325 | 2,313,448 | 1,512,500 | 289,888 |
Classification
21st company classification
BETA
Small company
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises